Long-Term Outcome of 335 Adult Patients Receiving Different Schedules of Imatinib and Chemotherapy as Front-Line Treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

被引：0

作者：

Pfeifer, Heike ^{[1
]}

Goekbuget, Nicola ^{[2
]}

Voelp, Christian ^{[1
]}

Huettmann, Andreas ^{[3
]}

Luebbert, Michael ^{[4
]}

Stuhlmann, Reingard ^{[5
]}

Dengler, Julanta ^{[6
]}

Kreuzer, Karl-Anton ^{[7
]}

Beck, Joachim ^{[8
]}

Stelljes, Matthias ^{[9
]}

Schmid, Mathias ^{[10
]}

Wassmann, B. ^{[1
]}

Leimer, Lothar ^{[11
]}

Spiekermann, Karsten ^{[12
]}

Terwey, Theis E. ^{[13
]}

Schaefer-Eckart, K. ^{[14
]}

Ditz, D. ^{[15
]}

Lindemann, H. ^{[16
]}

Morgner, A. ^{[17
]}

Schaich, Markus ^{[18
]}

Burmeister, Thomas ^{[19
]}

Binckebanck, A. ^{[1
]}

Hoelzer, Dieter

Ottmann, Oliver G. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Dept Med, Frankfurt, Germany

[2] Goethe Univ Hosp, Dept Med, Frankfurt, Germany

[3] Univ Hosp, D-45122 Essen, Germany

[4] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany

[5] Asklepios Klin St Georg, Hamburg, Germany

[6] Univ Heidelberg, Dept Hematol, Heidelberg, Germany

[7] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[8] Univ Hosp, Mainz, Germany

[9] Univ Munster, Munster, Germany

[10] Univ Hosp Ulm, Ulm, Germany

[11] Robert Bosch Krankenhaus, Stuttgart, Germany

[12] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany

[13] Charite, D-13353 Berlin, Germany

[14] Klinikum Nurnberg, Dept Hematol, Med Klin 5, Nurnberg, Germany

[15] Univ Regensburg, Regensburg, Germany

[16] Katholisches Krankenhaus Hagen, Dresden, Germany

[17] Krankenhaus Kuchwald Chemnitz, Dresden, Germany

[18] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[19] Univ Hosp Berlin, Charlie, Dept Hematol & Oncol, Berlin, Germany

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：79 / 79

页数：1

共 50 条

[41] Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL)
Thomas, D. A.
O'Brien, S. M.
Faderl, S.
Kashani, F. Ravandi
Wierda, W. G.
Andreeff, M.
Garris, R. S.
Champlin, R. E.
Cortes, J. E.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[42] Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph plus acute lymphoblastic leukemia (ALL) patients: Interim analysis of the GIMEMA prospective study LAL1205
Foa, Robert
Vignetti, Marco
Vitale, Antonella
Meloni, Giovanna
Guirini, Anna
De Propris, Stefania
Elia, Loredana
Cimino, Giuseppe
Luppi, Mario
Castagnola, Carlo
Sica, Simona
Nieddu, Rosa
Martinelli, Giovanni
Baccarani, Michele
BLOOD, 2007, 110 (11) : 10A - 10A
[43] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
Jabbour, Elias
Martinelli, Giovanni
Vignetti, Marco
Kantarjian, Hagop
Gomez-Almaguer, David
Minami, Yosuke
Dombret, Herve
Hennessy, Meliessa
Vorog, Alexander
Wang, Bingxia
Ribera, Josep-Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
[44] Prediction of response duration and survival during imatinib (Glivec) therapy by serial analysis of minimal residual disease (MRD) in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL).
Scheuring, UJ
Pfeifer, H
Wassmann, B
Brueck, P
Atta, J
Petershofen, EK
Gehrke, B
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
BLOOD, 2002, 100 (11) : 547A - 547A
[45] Imatinib mesylate as treatment of molecular relapse of Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) after stem cell transplantation
Wassmann, B
Scheuring, U
Pfeifer, H
Martin, H
Klein, SA
Binckebanck, A
Stadler, M
Hertenstein, B
Bomhäuser, M
Basara, N
Schwerdtfeger, R
Bunjes, D
Gschaidmeier, H
Hoelzer, D
Ottmann, OG
BONE MARROW TRANSPLANTATION, 2003, 31 : S171 - S172
[46] Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib
Ottmann, Oliver G.
Larson, Richard A.
Kantarjian, Hagop M.
le Coutre, Philipp
Baccarani, Michele
Haque, Ariful
Gallagher, Neil
Giles, Francis
BLOOD, 2007, 110 (11) : 828A - 828A
[47] Comparison of Long-Term Outcome between Imatinib and Dasatinib Prophylaxis after Allogeneic Stem Cell Transplantation in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia-a Multi-Center Retrospective Study
Guan, Fangshu
Yang, Luxin
Zhu, Panpan
Lai, Xiaoyu
Liu, Lizhen
Shi, Jimin
Zhao, Yanmin
Yu, Jian
Fu, Huarui
Zhao, Yi
Lan, Jianping
Chen, Yi
Lu, Ying
Ouyang, Guifang
Xu, Yang
Qiu, Xi
Cai, Zhen
Huang, He
Luo, Yi
BLOOD, 2023, 142
[48] A randomized study comparing two schedules of Imatinib Intervention after allogeneic stem cell transplantation (SCT) for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph plus ALL)
Pfeifer, H.
Wassmann, B.
Bethge, W.
Dengler, J.
Bornhaeuser, M.
Stadler, M.
Beelen, D.
Guenther, A.
Vucinic, V.
Burmeister, T.
Stelljes, M.
Schwerdtfeger, R.
Schaefer-Eckhart, K.
Bader, P.
Kreyenberg, H.
Schuld, P.
Serve, H.
Hoelzer, D.
Goekbuget, N.
Ottmann, O. G.
ONKOLOGIE, 2011, 34 : 15 - 16
[49] Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Ravandi, Farhad
O'Brien, Susan M.
Cortes, Jorge E.
Thomas, Deborah M.
Garris, Rebecca
Faderl, Stefan
Burger, Jan A.
Rytting, Michael E.
Ferrajoli, Alessandra
Wierda, William G.
Verstovsek, Srdan
Champlin, Richard
Kebriaei, Partow
McCue, Deborah A.
Huang, Xuelin
Jabbour, Elias
Garcia-Manero, Guillermo
Estrov, Zeev
Kantarjian, Hagop M.
CANCER, 2015, 121 (23) : 4158 - 4164
[50] CHARACTERISTICS OF PONATINIB THERAPY FOR PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL) PATIENTS IN REAL-WORLD CLINICAL PRACTICE COMPARED TO THE PACE TRIAL
Mauro, M.
McGarry, L. J.
Yang, M.
Lustgarten, S.
Huang, H.
HAEMATOLOGICA, 2016, 101 : 355 - 355

← 1 2 3 4 5 →